Key result
The SARS-CoV-2 NSP6 L260F mutation enhanced viral RNA replication up to 1000-fold in vitro and significantly increased pathogenesis in mice, causing 100% mortality compared to 20% in the revertant.
Why the study?
Non-Spike mutations are accumulating across the SARS-CoV-2 genome, but their functional impact remains not well understood.
The L260F mutation in NSP6 enhances SARS-CoV-2 RNA replication and pathogenesis, suggesting a compensatory mechanism for reduced viral entry functions in recent Omicron variants.
Answers are grounded in this paper and cite their sources.
Recent Omicron variants show enhanced non-Spike RNA replication; leaves open whether NSP6 L260F drives transmission or pathogenesis in humans.
The COVID-19 pandemic has been driven by SARS-CoV-2 variants with enhanced transmission and immune escape. Apart from extensive evolution in the Spike protein, non-Spike mutations are accumulating across the entire viral genome and their functional impact is not well understood. To address the contribution of these mutations, we reconstructed genomes of recent Omicron variants with disabled Spike expression (replicons) to systematically compare their RNA replication capabilities independently from Spike. We also used a single reference replicon and complemented it with various Omicron variant Spike proteins to quantify viral entry capabilities in single-round infection assays. Viral entry and RNA replication were negatively correlated, suggesting that as variants evolve reduced entry functions under growing immune pressure on Spike, RNA replication increases as a compensatory mechanism. We identified multiple mutations across the viral genome that enhanced viral RNA replication. NSP6 emerged as a hotspot with a distinct L260F mutation independently arising in the BQ.1.1 and XBB.1.16 variants. Using mutant and revertant NSP6 viral clones, the L260F mutation was validated to enhance viral replication in cells and increase pathogenesis in mice. Notably, this mutation reduced host lipid droplet content by NSP6. Collectively, a systematic analysis of RNA replication of recent Omicron variants defined NSP6's key role in viral RNA replication that provides insight into evolutionary trajectories of recent variants with possible therapeutic implications.
No takes yet. Share an insight, caveat, or question.
Taha et al. (2025) studied SARS-CoV-2 infection. NSP6 L260F mutation vs. Wild-type or revertant virus (NSP6 F260L) was evaluated on Viral RNA replication and pathogenesis. The SARS-CoV-2 NSP6 L260F mutation enhanced viral RNA replication up to 1000-fold in vitro and significantly increased pathogenesis in mice, causing 100% mortality compared to 20% in the revertant.
Synapse has enriched 5 related papers. Consider them for comparative context: